Mode
Text Size
Log in / Sign up
Phase 2 N=107 Randomized Quadruple-blind Prevention

Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents

Respiratory Infection

Enrolled (actual)
107
Serious AEs
20.6%
Results posted
Apr 2017
Primary outcome: Primary: Number of Acute Respiratory Infections (ARIs) — 32; 48 events

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
High Dose Vitamin D (Drug); Standard Dose Vitamin D (Drug); Placebo (Drug); Usual Care (Dietary_supplement)
Age
Adult, Older Adult · 60+ yrs
Sex
All
Sponsor
University of Colorado, Denver
Primary completion
Aug 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Acute Respiratory Infections (ARIs)
32; 48
SECONDARY
Severity of Acute Respiratory Infections
3; 6
SECONDARY
Time to First ARI
0.59; 1.00
SECONDARY
Change in 25-hydroxyvitamin D (25OHD) Level
8.18; 2.71
SECONDARY
Change in Parathyroid Hormone Level
SECONDARY
Falls
70; 27
SECONDARY
Fractures
5; 8
SECONDARY
Number of Upper Respiratory Infections
21; 36
SECONDARY
Number of Lower Respiratory Infections
11; 12
SECONDARY
Number of Influenza-like Illnesses
SECONDARY
Incident Kidney Stones
0; 0
SECONDARY
Incident Hypercalcemia
0; 0
SECONDARY
Death
9; 13
SECONDARY
Number of Urinary Tract Infections
38; 22
SECONDARY
Number of Other Infections
33; 43

Summary

This study will test the role of high dose vitamin D supplementation in prevention of acute respiratory infection in older nursing home residents. The investigators hypothesize that residents on high dose vitamin D supplementation will have a lower incidence of acute respiratory infection that those on standard dose vitamin D supplementation.

Eligibility Criteria

Inclusion Criteria

  • Age 60+ years
  • Resides in nursing home

Exclusion Criteria

  • Terminal illness (expected survival 1, 000 IU/d vitamin D supplementation
  • History (or strong family history) of kidney stones
  • History of sarcoidosis or other granulomatous disorders associated with hypercalcemia
  • Elevated baseline hypercalcemia (albumin-adjusted serum calcium >10.5 mg/dL)
  • Baseline serum 25OHD level ≥ 100 nmol/L
  • Inability to provide informed consent and no available healthcare legally authorized representative
  • Inability of participant or legally authorized representative to speak/understand English
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01102374). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search